21st century tumor models

21st century cancer research requires 21st century model cell lines

In context of our ongoing clinical research activities, we are building a comprehensive collection of new cancer model cell lines to serve the needs of cancer research and drug development. In parallel to collection of tumor samples for ex vivo drug efficacy testing, we´ve established a proprietary cell line repository consisting of 150+ cell lines representing 45+ different human cancers (@01/2026); the MISB Cancer Cell Line Panel. The continuously expanding MISB cell line panel has been characterized extensively in context of Misvik’s Precision Oncology initiative including using DNA and RNA sequencing and extensive drug screens of hundreds of cancer therapies, including the very latest novel cancer drugs. The MISB cell line panel offers a collection of low-passage clinically relevant tumor cell models that retain the original patient-specific tumor biology including lineage heterogeneity, genetic background and treatment history (62 different therapies covered as previous line of treatment before relapse and establishment of cell line). The MISB cell line panel is offered for rapid large scale high-throughput cell panel screening, in-depth studies of drug efficacy and combinatorial synergy as well as for genome-wide loss of function genomic screening using siRNA and CRISPR.

Common and rare cancers

The common cancer types included in the current MISB cell line panel (@01/2026) include: Bladder, Breast, Cholangiocarcinoma, Colon, Esophageal, Endometrial, Glioma, Head and Neck, Lung, Melanoma, Ovarian, Pancreatic, Prostate and Renal. Rare cancer types include: Conjunctival melanoma, Choroidal melanoma, DSRCT, GIST, Ileocecal valve, Large Cell Neuroendocrine PCa, Salivary gland, Sarcomas, Urachal and cancers of unknown origin. 

Patient derived functional tumor models retain the cellular composition and differentiation state heterogeneity of the parental tumors. Primary ex vivo models also reflect the  pathology and clinical behavior of the cancer. Misvik´s ex vivo tumor models are a continuously expanding collection of early passage patient derived functional tumor models cryopreserved following initial tissue dissociation and establishment of organoid culture. The ex vivo model collection currently contains 700+ tumor samples representing 90+ different solid cancer types including rare to ultra rare cancers. The sample series also contains matched longitudinal samples from the same patient prior and after treatment allowing study of therapy efficacy in treatment naive and relapsed tumor models. All samples are incorporated on Misvik´s master RPPA (reverse-phase-protein array) sample repository for rapid target evaluation and general protein expression analysis across different cancers types.

Ex vivo tumor models reflect disease characteristics of the current patient populations receiving latest novel cancer therapies as the standard care. All available clinical annotations are collected from all ex vivo models and coupled with next-generation molecular profiling and histopathology. This allows selection and study of models that recapitulate the research question and clinical need of today´s oncology drug discovery and cancer research. The ex vivo drug screening results are always correlated with the available clinical, molecular and histopathological information to facilitate biomarker discovery and indication categorization. The ex vivo tumor models are available for large-scale pan-cancer screens or standalone studies of any molecular entity including novel immuno-oncology therapies as the models incorporate the tumor tissues full cellular complexity.